Alzinova Q2 - Progress toward phase II study

Redeye provides a research update following the Q2 report published by Alzinova earlier today. The company reported an increased cash burn as it intensifies its preparations ahead of the upcoming phase II study. The company has now selected a qualified CRO and submitted an IND for the trial as it continues to look for a financing solution for the study, preferably through a licensing deal for ALZ-101. We reiterate our fair value range (SEK1 – SEK10) with a base case valuation of SEK5.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/